ALCAM/CD166 is a TGF-β-responsive Marker and Functional Regulator of Prostate Cancer Metastasis to Bone

Overview

Journal Cancer Res

Specialty Oncology

Date 2014 Jan 4

PMID 24385212

Citations 42

Authors

Amanda G Hansen

Shanna A Arnold

Ming Jiang

Trenis D Palmer

Tatiana Ketova

Alyssa Merkel

Michael Pickup

Susan Samaras

Yu Shyr

Harold L Moses

Simon W Hayward

Julie A Sterling

Andries Zijlstra

Affiliations

Soon will be listed here.

Abstract

The dissemination of prostate cancer to bone is a common, incurable aspect of advanced disease. Prevention and treatment of this terminal phase of prostate cancer requires improved molecular understanding of the process as well as markers indicative of molecular progression. Through biochemical analyses and loss-of-function in vivo studies, we demonstrate that the cell adhesion molecule, activated leukocyte cell adhesion molecule (ALCAM), is actively shed from metastatic prostate cancer cells by the sheddase ADAM17 in response to TGF-β. Not only is this posttranslational modification of ALCAM a marker of prostate cancer progression, the molecule is also required for effective metastasis to bone. Biochemical analysis of prostate cancer cell lines reveals that ALCAM expression and shedding is elevated in response to TGF-β signaling. Both in vitro and in vivo shedding is mediated by ADAM17. Longitudinal analysis of circulating ALCAM in tumor-bearing mice revealed that shedding of tumor, but not host-derived ALCAM is elevated during growth of the cancer. Gene-specific knockdown of ALCAM in bone-metastatic PC3 cells greatly diminished both skeletal dissemination and tumor growth in bone. The reduced growth of ALCAM knockdown cells corresponded to an increase in apoptosis (caspase-3) and decreased proliferation (Ki67). Together, these data demonstrate that the ALCAM is both a functional regulator as well as marker of prostate cancer progression.

Citing Articles

Cross-Talk between the TGF-β and Cell Adhesion Signaling Pathways in Cancer.

Liao J, Chen R, Lin B, Deng R, Liang Y, Zeng J Int J Med Sci. 2024; 21(7):1307-1320.

PMID: 38818471 PMC: 11134594. DOI: 10.7150/ijms.96274.

sBioSITe enables sensitive identification of the cell surface proteome through direct enrichment of biotinylated peptides.

Garapati K, Ding H, Charlesworth M, Kim Y, Zenka R, Saraswat M Clin Proteomics. 2023; 20(1):56.

PMID: 38053024 PMC: 10696767. DOI: 10.1186/s12014-023-09445-6.

Exploration of diagnostic biomarkers, microenvironment characteristics, and ursolic acid's therapeutic effect for benign prostate hyperplasia.

Chen Y, Xu H, Xu H, Liu C, Zhan M, Wang Z Int J Biol Sci. 2023; 19(13):4242-4258.

PMID: 37705744 PMC: 10496513. DOI: 10.7150/ijbs.85739.

Tissue-specific cancer stem/progenitor cells: Therapeutic implications.

Yehya A, Youssef J, Hachem S, Ismael J, Abou-Kheir W World J Stem Cells. 2023; 15(5):323-341.

PMID: 37342220 PMC: 10277968. DOI: 10.4252/wjsc.v15.i5.323.

Biological and Clinical Aspects of Metastatic Spinal Tumors.

Litak J, Czyzewski W, Szymoniuk M, Sakwa L, Pasierb B, Litak J Cancers (Basel). 2022; 14(19).

PMID: 36230523 PMC: 9559304. DOI: 10.3390/cancers14194599.

References

Jin J, Dayyani F, Gallick G . Steps in prostate cancer progression that lead to bone metastasis. Int J Cancer. 2011; 128(11):2545-61. PMC: 3082284. DOI: 10.1002/ijc.26024. View

Soond S, Everson B, Riches D, Murphy G . ERK-mediated phosphorylation of Thr735 in TNFalpha-converting enzyme and its potential role in TACE protein trafficking. J Cell Sci. 2005; 118(Pt 11):2371-80. DOI: 10.1242/jcs.02357. View

Tachezy M, Effenberger K, Zander H, Minner S, Gebauer F, Vashist Y . ALCAM (CD166) expression and serum levels are markers for poor survival of esophageal cancer patients. Int J Cancer. 2011; 131(2):396-405. DOI: 10.1002/ijc.26377. View

Ott G, Asakawa N, Lu Z, Anand R, Liu R, Covington M . Potent, exceptionally selective, orally bioavailable inhibitors of TNF-alpha Converting Enzyme (TACE): novel 2-substituted-1H-benzo[d]imidazol-1-yl)methyl)benzamide P1' substituents. Bioorg Med Chem Lett. 2008; 18(5):1577-82. DOI: 10.1016/j.bmcl.2008.01.075. View

Ashby W, Wikswo J, Zijlstra A . Magnetically attachable stencils and the non-destructive analysis of the contribution made by the underlying matrix to cell migration. Biomaterials. 2012; 33(33):8189-203. PMC: 3444626. DOI: 10.1016/j.biomaterials.2012.07.018. View

King J, Ofori-Acquah S, Stevens T, Al-Mehdi A, Fodstad O, Jiang W . Activated leukocyte cell adhesion molecule in breast cancer: prognostic indicator. Breast Cancer Res. 2004; 6(5):R478-87. PMC: 549164. DOI: 10.1186/bcr815. View

Li H, Jiang M, Honorio S, Patrawala L, Jeter C, Calhoun-Davis T . Methodologies in assaying prostate cancer stem cells. Methods Mol Biol. 2009; 568:85-138. DOI: 10.1007/978-1-59745-280-9_7. View

Campbell J, Merkel A, Masood-Campbell S, Elefteriou F, Sterling J . Models of bone metastasis. J Vis Exp. 2012; (67):e4260. PMC: 3490264. DOI: 10.3791/4260. View

Varambally S, Yu J, Laxman B, Rhodes D, Mehra R, Tomlins S . Integrative genomic and proteomic analysis of prostate cancer reveals signatures of metastatic progression. Cancer Cell. 2005; 8(5):393-406. DOI: 10.1016/j.ccr.2005.10.001. View

10.

Rosso O, Piazza T, Bongarzone I, Rossello A, Mezzanzanica D, Canevari S . The ALCAM shedding by the metalloprotease ADAM17/TACE is involved in motility of ovarian carcinoma cells. Mol Cancer Res. 2008; 5(12):1246-53. DOI: 10.1158/1541-7786.MCR-07-0060. View

11.

van Kempen L, Nelissen J, Degen W, Torensma R, Weidle U, Bloemers H . Molecular basis for the homophilic activated leukocyte cell adhesion molecule (ALCAM)-ALCAM interaction. J Biol Chem. 2001; 276(28):25783-90. DOI: 10.1074/jbc.M011272200. View

12.

Minner S, Kraetzig F, Tachezy M, Kilic E, Graefen M, Wilczak W . Low activated leukocyte cell adhesion molecule expression is associated with advanced tumor stage and early prostate-specific antigen relapse in prostate cancer. Hum Pathol. 2011; 42(12):1946-52. DOI: 10.1016/j.humpath.2011.02.017. View

13.

Lunter P, van Kilsdonk J, van Beek H, Cornelissen I, Bergers M, Willems P . Activated leukocyte cell adhesion molecule (ALCAM/CD166/MEMD), a novel actor in invasive growth, controls matrix metalloproteinase activity. Cancer Res. 2005; 65(19):8801-8. DOI: 10.1158/0008-5472.CAN-05-0378. View

14.

Nakagawa T, Kollmeyer T, Morlan B, Anderson S, Bergstralh E, Davis B . A tissue biomarker panel predicting systemic progression after PSA recurrence post-definitive prostate cancer therapy. PLoS One. 2008; 3(5):e2318. PMC: 2565588. DOI: 10.1371/journal.pone.0002318. View

15.

Kim I, Ahn H, Zelner D, Shaw J, Sensibar J, Kim J . Genetic change in transforming growth factor beta (TGF-beta) receptor type I gene correlates with insensitivity to TGF-beta 1 in human prostate cancer cells. Cancer Res. 1996; 56(1):44-8. View

16.

Hu Z, Gupta J, Zhang Z, Gerseny H, Berg A, Chen Y . Systemic delivery of oncolytic adenoviruses targeting transforming growth factor-β inhibits established bone metastasis in a prostate cancer mouse model. Hum Gene Ther. 2012; 23(8):871-82. PMC: 3413899. DOI: 10.1089/hum.2012.040. View

17.

Onder T, Gupta P, Mani S, Yang J, Lander E, Weinberg R . Loss of E-cadherin promotes metastasis via multiple downstream transcriptional pathways. Cancer Res. 2008; 68(10):3645-54. DOI: 10.1158/0008-5472.CAN-07-2938. View

18.

Uhlen M, Oksvold P, Fagerberg L, Lundberg E, Jonasson K, Forsberg M . Towards a knowledge-based Human Protein Atlas. Nat Biotechnol. 2010; 28(12):1248-50. DOI: 10.1038/nbt1210-1248. View

19.

Witzel I, Schroder C, Muller V, Zander H, Tachezy M, Ihnen M . Detection of activated leukocyte cell adhesion molecule in the serum of breast cancer patients and implications for prognosis. Oncology. 2012; 82(6):305-12. DOI: 10.1159/000337222. View

20.

Hansen A, Swart G, Zijlstra A . ALCAM: Basis Sequence: Mouse. AFCS Nat Mol Pages. 2015; 2011. PMC: 4432864. DOI: 10.1038/mp.a004126.01. View